Legend Biotech
A global clinical-stage biopharmaceutical company engaged in the discovery and development of new cell therapies for oncology and other indications that was spun out of Hong Kong-listed GenScript Biotech.
The US company is engaged in a strategic collaboration with the Johnson & Johnson unit Janssen Biotech to develop and commercialize its lead product candidate, LCAR-B38M/JNJ-4528.
This is an investigational BCMA-targeted CAR-T cell therapy for patients living with relapsed or refractory multiple myeloma. It is currently being studied in registrational clinical trials.
Latest Legend Biotech News & Features
28 June 2024
25 June 2024
21 June 2024
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze